Literature DB >> 8483882

H-ras-1 point mutations in soft tissue sarcomas.

W Wilke1, M Maillet, R Robinson.   

Abstract

The H-ras-1 protooncogene is activated by single base substitutions occurring in either codon 12, 13, or 61. These mutations have been described with varying frequencies in several human tumor types. Since ras oncogenes were first discovered as the transforming sequences of Harvey and Kirsten murine sarcoma viruses (which also contain activating point mutations compared to the homologous cellular sequences), we wished to investigate the possibility that ras mutations might also occur in human sarcomas. We extracted DNA from six malignant fibrous histiocytomas (MFH), three embryonal rhabdomyosarcomas (ER), one alveolar rhabdomyosarcoma, one pleomorphic rhabdomyosarcoma, and one leiomyosarcoma. The DNA from regions flanking codons 12/13 and codon 61 was amplified by the polymerase chain reaction and sequenced with an automated DNA sequencer. As controls, we amplified and sequenced normal DNA (placenta) and DNA with known point mutations (T24 bladder carcinoma cells). We found three cases with mutations, all occurring in codon 12. One ER showed a G-to-T mutation in the second position of codon 12 (coding for valine instead of glycine). Two MFHs showed G-to-A mutations in the second position of codon 12 (coding for aspartic acid instead of glycine). Although a limited number of cases were sampled, we conclude that study of H-ras-1 mutations may be relevant to MFH and ER. Additional studies of N and K-ras mutations as well as more cases investigating H-ras will be required before we can ascertain the significance of ras mutations in the oncogenesis of human soft tissue sarcomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8483882

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  12 in total

1.  Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations.

Authors:  P Rieske; J Bartkowiak; A Szadowska; M Debiec-Rychter
Journal:  Mol Pathol       Date:  1999-04

Review 2.  Primary malignant fibrous histiocytoma of the pancreas: a case with K-ras mutation and a review of the literature.

Authors:  Tomotaka Akatsu; Masashi Tsugita; Seiichi Ro; Kaori Kameyama; Masaki Kitajima
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 3.  Developmental origins of fusion-negative rhabdomyosarcomas.

Authors:  Ken Kikuchi; Brian P Rubin; Charles Keller
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

4.  Single somatic ras gene point mutation in soft tissue malignant fibrous histiocytomas.

Authors:  R M Bohle; S Brettreich; R Repp; A Borkhardt; H Kosmehl; H M Altmannsberger
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

Review 5.  New advances in the molecular biology of musculoskeletal neoplasms.

Authors:  J A Morcuende; J A Buckwalter
Journal:  Iowa Orthop J       Date:  1997

6.  Chromosomal and genetic imbalances in synovial sarcoma detected by conventional and microarray comparative genomic hybridization.

Authors:  Yasuko Nakagawa; Kunihiko Numoto; Aki Yoshida; Toshiyuki Kunisada; Hidenori Ohata; Ken Takeda; Daniel Wai; Christopher Poremba; Toshifumi Ozaki
Journal:  J Cancer Res Clin Oncol       Date:  2006-03-24       Impact factor: 4.553

7.  Mutational status of K-ras and TP53 genes in primary sarcomas of the heart.

Authors:  J M Garcia; R Gonzalez; J M Silva; G Dominguez; I S Vegazo; C Gamallo; M Provencio; P España; F Bonilla
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

Review 8.  Rhabdomyosarcomas: an overview on the experimental animal models.

Authors:  Alessandra Zanola; Stefania Rossi; Fiorella Faggi; Eugenio Monti; Alessandro Fanzani
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

Review 9.  Caveolins in rhabdomyosarcoma.

Authors:  Stefania Rossi; Pietro Luigi Poliani; Cristina Missale; Eugenio Monti; Alessandro Fanzani
Journal:  J Cell Mol Med       Date:  2011-12       Impact factor: 5.310

10.  Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.

Authors:  Katherine K Slemmons; Lisa E S Crose; Erin Rudzinski; Rex C Bentley; Corinne M Linardic
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.